Loading...

Estrella Immunopharma, Inc.

ESLAW•NASDAQ
HealthcareBiotechnology
$0.05
$0.01(29.18%)

Estrella Immunopharma, Inc. (ESLAW) Stock Overview

Explore Estrella Immunopharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for ESLAWStats details for ESLAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ESLAWAnalyst Recommendations details for ESLAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

CEO

Dr. Cheng Liu Ph.D.

Headquarters

5858 Horton Street, EmeryVille, CA

Founded

1970

Frequently Asked Questions